Penny stocks and low-priced shares (under $5) are known for high volatility, driven by news catalysts, earnings, clinical updates, or IPO activity. This week featured several with sharp price swings, heavy volume, and momentum, particularly in biotech and retail sectors. Here are four that stood out, based on recent trading activity and developments. Note that these are speculative and carry significant risk—always do your own research. finance.yahoo.com tipranks.com
1. HCW Biologics Inc. (HCWB) – Biotech Surge on Funding and Pipeline Momentum
HCWB, a clinical-stage biopharma company focused on immunotherapeutics for cancer, autoimmune diseases, and age-related conditions, saw explosive gains. Shares surged over 129% in a single session around May 20–21, closing near $2.43 at one point with massive volume exceeding 190 million shares. wallstreetzen.com finance.yahoo.com
Key drivers: The company announced a ~$4 million private placement offering and reported Q1 2026 results with revenue from licensing deals. Positive preclinical data on candidates like HCW11-040 (for bronchopulmonary dysplasia) added fuel. The stock had been rallying on broader biotech momentum and Nasdaq compliance updates earlier. investors.hcwbiologics.com
At prices around $2–$3, HCWB remains a micro-cap play with high risk/reward tied to clinical progress. Trading volume spiked dramatically, signaling strong retail and speculative interest.
2. Leslie’s, Inc. (LESL) – Pool Retailer Jumps on Earnings Beat
LESL, the pool and spa supplies retailer, experienced a dramatic short-term move. Shares more than doubled intraday at one point (up ~145% in a session) following its Q2 2026 earnings report around mid-May, with prices fluctuating in the $2–$4 range. finance.yahoo.com marketbeat.com
Key drivers: The company reported a 4.3% sales increase and 6.6% comparable sales growth, beating expectations amid a “Price Drop” initiative and traffic gains. Analysts raised price targets (e.g., to $3), though adjusted EPS missed slightly. High short interest contributed to squeeze dynamics. cnbc.com
LESL trades under $4 recently, with a modest market cap, making it sensitive to seasonal retail trends in the pool industry. Volatility remains elevated post-earnings.
3. MetaVia Inc. (MTVA) – Obesity Drug Biotech with Clinical Catalysts
MTVA (formerly related to metabolic therapies) climbed sharply, with gains of 50%+ in sessions around May 20–21, reaching prices near $2.89–$3.80 on heavy volume (tens of millions of shares). tipranks.com finance.yahoo.com
Key drivers: Positive data on its DA-1726 obesity candidate (strong Phase 1 weight-loss results) and peer-reviewed publications on vanoglipel for MASH (liver disease/fibrosis). Presentations at conferences like ADA 2026 and analyst Buy ratings with high price targets (up to $20) boosted sentiment. Q1 financial updates showed progress in its cardiometabolic pipeline. stocktitan.net
Trading under $4, MTVA is a classic biotech penny/mid-penny stock where news flow on obesity/MASH assets drives rapid moves.
4. VIDA Global Inc. (VIDA) – Fresh IPO with Post-Listing Action
VIDA, an AI Agent Operating System company for businesses, debuted via IPO in mid-May at $4.00 per share and showed post-listing volatility, trading in the $3.50–$4.50 range with insider buying and volume spikes. prnewswire.com
Key drivers: The IPO closed successfully, with shares beginning trading on NYSE American. A director purchased 63,000 shares shortly after, and the company highlighted its AI platform. As a new listing, it attracted speculative interest in the AI/tech sector. stocktitan.net
At under $5, VIDA offers exposure to emerging AI applications but faces typical new-IPO risks like lock-up expirations and execution challenges.
Key Takeaways and Risks
These stocks highlight themes in biotech innovation (HCWB, MTVA), consumer retail recovery (LESL), and AI/tech (VIDA). Moves were amplified by low floats, high short interest in some cases, and news catalysts amid broader market interest in small-caps. However, stocks under $5 are prone to sharp reversals, dilution, and liquidity issues. Many have limited earnings or high cash burn. finance.yahoo.com
This is not investment advice—prices can change rapidly, and past performance (or this week’s moves) is no guarantee of future results. Consult a financial advisor and review SEC filings for the latest details. Market conditions as of late May 2026.